320 related articles for article (PubMed ID: 25427163)
1. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
2. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
3. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H
Transplantation; 2006 Oct; 82(8):1093-100. PubMed ID: 17060859
[TBL] [Abstract][Full Text] [Related]
4. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
5. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
6. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
7. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
8. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
[TBL] [Abstract][Full Text] [Related]
9. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
Wheless SA; Gulley ML; Raab-Traub N; McNeillie P; Neuringer IP; Ford HJ; Aris RM
Am J Respir Crit Care Med; 2008 Nov; 178(10):1060-5. PubMed ID: 18755927
[TBL] [Abstract][Full Text] [Related]
11. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
12. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
[TBL] [Abstract][Full Text] [Related]
13. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
[TBL] [Abstract][Full Text] [Related]
15. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant Lymphoproliferative Disorder in Pediatric Patients: Characteristics of Disease in EBV-seropositive Recipients.
L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Yeung S; Stephens D; Punnett AS; Barton M; Allen UD
Transplantation; 2019 Nov; 103(11):e369-e374. PubMed ID: 31385930
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
[TBL] [Abstract][Full Text] [Related]
19. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.
Babel N; Vergopoulos A; Trappe RU; Oertel S; Hammer MH; Karaivanov S; Schneider N; Riess H; Papp-Vary M; Neuhaus R; Gondek LP; Volk HD; Reinke P
Transplantation; 2007 Aug; 84(3):387-91. PubMed ID: 17700165
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
